← Leaderboards
Arnab Kumar Chatterjee
Washington University
$11,706,278
Attributed
$15,027,700
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $73.2M · FY2020–25$100M$75M$50M$25M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$82,651,856 · 4
By mechanism
U19$72,025,302 · 2
R01$6,642,844 · 1
N01$3,983,710 · 1
Top collaborators
- L David Sibley6 shared
- Sumit K Chanda1 shared
- Adolfo Garcia-Sastre1 shared
Most similar at Washington University
Same institution · by research overlap
- L David Sibley$48,261,605
- James W Janetka$9,104,937
- Adrianus Cm Boon$7,930,780
- Christopher F Basler$44,557,002
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoIn VitroPharmaceutical PreparationsPre-ClinicalDrug CandidateOralIn Vivo EvaluationAnimal ModelEfficacy TestingSmall Molecule LibrariesCellsLeadFutureMouse ModelBiological AvailabilityInfectionCystAnimalsDesignChemical SynthesisCongenital InfectionAnalogClinicAzetidine
Grant awards (10)
Rational Systemic Characterization and Selection of Adjuvants for HIV Vaccine Candidates (R-CASA)$1,992,875
N01 · FY2025 · AI · contact PI
Exploiting Diversity-Oriented Chemical Synthesis for Combating Chronic Parasitic Infection$1,228,981
R01 · FY2025 · AI
Rational Systemic Characterization and Selection of Adjuvants for HIV Vaccine Candidates (R-CASA)$1,990,835
N01 · FY2024 · AI · contact PI
Exploiting Diversity-Oriented Chemical Synthesis for Combating Chronic Parasitic Infection$939,834
R01 · FY2024 · AI
Exploiting Diversity-Oriented Chemical Synthesis for Combating Chronic Parasitic Infection$1,136,794
R01 · FY2023 · AI
Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)$67,624,156
U19 · FY2022 · AI
Inhibitors of SARS-CoV-2 proteases$4,401,146
U19 · FY2022 · AI · contact PI
Exploiting Diversity-Oriented Chemical Synthesis for Combating Chronic Parasitic Infection$1,137,363
R01 · FY2022 · AI
Exploiting Diversity-Oriented Chemical Synthesis for Combating Chronic Parasitic Infection$1,137,472
R01 · FY2021 · AI
Exploiting Diversity-Oriented Chemical Synthesis for Combating Chronic Parasitic Infection$1,062,400
R01 · FY2020 · AI